After six months of outperformance, it seems investors are still only discounting low to average potential in BioTech and Life Science stocks
Biotech and Life Science indexes finally moving out of the shadow, but unfortunately, not all investors nor companies are affected
Biotech and Life Science stocks takes a pause while underlying deal activity shows no sign of stopping